today announced the presentation of new Phase 1 clinical trial data of its CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma. The presentation at the 63 rd ...

today announced that it has dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with the Tn/STn glycoform of mucin 1 (TnMUC1) chimeric antigen receptor T-cell (CAR-T) therapy in ...